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Background:  Carriers of a reduced-function CYP2C19 allele are shown to have diminished platelet inhibition and higher rate of clinical risk. We 
hypothesized that optimal cut-off value showing effective inhibition of on-clopidogrel platelet aggregation might be determined by calculating the 
cut-off value of on-clopidogrel platelet aggregation in carriers of CYP2C19 reduced-function allele.
Methods and Results:  We enrolled 177 consecutive coronary artery disease (CAD) patients who received dual-antiplatelet therapy with both 
aspirin and clopidogrel. We examined CYP2C19 genotype and residual platelet aggregation by using VerifyNow P2Y12 system. Frequency of CYP2C19 
reduced-function allele was 65% in carriers and 35% in noncarriers. Platelet inhibition measured by P2Y12 reaction units (PRU) and % inhibition 
calculated as (1-PRU/Base) x100, was diminished in carriers compared with noncarriers (293.3±83.2 vs 216.6±75.6, p<0.0001, 18.1±18.9 vs 
36.6±21.8, p<0.0001, respectively). By multiple logistic regression analysis, PRU and % inhibition were significantly associated with carrier [odds 
ratio (OR) 4.85; 95% confidence interval (CI): 1.41 to 14.95; p=0.0060, OR 4.22; 95% CI: 1.41 to 12.62; p=0.00996, respectively]. In receiver-
operating characteristic analysis, PRU and % inhibition were significant predictors of carrier [area under the curve (AUC) 0.744; p<0.0001, AUC 
0.721; p<0.0001, respectively]. Cut-off PRU and % inhibition levels were 259.5 and 25.4%.
Conclusions:  These results suggested that Cut-off PRU and % inhibition levels might be useful indicators as optimal antiplatelet therapy with 
clopidogrel in stable CAD patients.
